LaFleur & Godfrey LLC Has $9.14 Million Stock Holdings in STERIS plc $STE

LaFleur & Godfrey LLC decreased its position in STERIS plc (NYSE:STE) by 11.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,927 shares of the medical equipment provider’s stock after selling 4,800 shares during the quarter. LaFleur & Godfrey LLC’s holdings in STERIS were worth $9,137,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Mediolanum International Funds Ltd grew its position in shares of STERIS by 9.0% in the second quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock valued at $14,883,000 after purchasing an additional 5,156 shares during the last quarter. Entropy Technologies LP lifted its position in shares of STERIS by 282.2% during the 2nd quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock worth $2,186,000 after purchasing an additional 6,718 shares during the last quarter. Vanguard Group Inc. boosted its stake in STERIS by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after purchasing an additional 205,276 shares during the period. Asset Management One Co. Ltd. grew its holdings in STERIS by 5.4% in the 3rd quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider’s stock valued at $24,366,000 after buying an additional 5,072 shares during the last quarter. Finally, Cerity Partners LLC increased its position in STERIS by 28.8% in the 3rd quarter. Cerity Partners LLC now owns 96,853 shares of the medical equipment provider’s stock worth $23,966,000 after buying an additional 21,656 shares during the period. 94.69% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

STE has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $275.20.

STERIS Stock Down 0.3%

Shares of STE stock opened at $250.55 on Monday. STERIS plc has a one year low of $204.90 and a one year high of $269.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The stock has a fifty day moving average price of $256.10 and a 200 day moving average price of $251.48. The stock has a market cap of $24.57 billion, a P/E ratio of 34.94 and a beta of 1.03.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The company’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s dividend payout ratio (DPR) is currently 35.15%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.